Luca Facchetti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Luca Facchetti has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Júlio Brandão Guimarães
Division of Musculoskeletal Radiology of Imaging Diagnosis, Department of Escola Paulista de Medicina, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil
4 shared publications - Alexandra S. Gersing
Department of Radiology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
3 shared publications - Benedikt J. Schwaiger
Department of Neuroradiology, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, 81675 Munich, Germany
3 shared publications - Thomas M. Link
Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA
3 shared publications - Gabby. B. Joseph
Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA
2 shared publications - Lorenzo Nardo
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States
2 shared publications
Latest Publications
- 8 September 2020
- Published by Springer Nature in Skeletal Radiology
- Vol. 50 (3) , 551-558
Meniscal ramp lesions: frequency, natural history, and the effect on knee cartilage over 2 years in subjects with anterior cruciate ligament tears
Purpose (i) To investigate the frequency and natural evolution of meniscal ramp lesions (MRLs) on MRI in subjects with acute ACL tear and (ii) to compare knee cartilage compositional degeneration between subjects with MRLs and subjects without meniscal pathology over 2 years. Materials and methods Fifty-seven subjects with ACL tears (32 females; age 32.6 ± 8.3 years; BMI 24.5 ± 3.5 kg/m2) from a prospective study were screened for the presence of MRLs. Morphological (high-resolution 3D fast spin-echo) and compositional (T1ρ and T2 mapping) MRI was performed prior to and 2 years after ACL reconstruction. Follow-up MR images were assessed for changes in the signal intensity of the MRLs and the presence of meniscal tears. Differences of compositional parameters were compared between subjects with MRLs and without meniscal lesions using independent samples t tests. Results MRLs were found in 16% (9/56) of the subjects with ACL tears at baseline. Only one subject with MRLs developed a posterior horn meniscal tear over 2 years. In 12 knees, no meniscal tears were found, which were defined as controls. Most interestingly, cartilage ∆T1ρ of the medial femur and medial tibia increased significantly more in subjects with MRLs compared with controls (mean difference, MF = 6.0 ± 0.8 vs. 2.3 ± 0.6, p = 0.004, and MT = 4.4 ± 1.4 vs. 0.4 ± 0.6, p = 0.027) and medial femur ∆T2 over 2 years increased significantly more in MRL than in control knees (5.1 ± 2.5 ms vs. 2.2 ± 1.9 ms, p = 0.012). Conclusion Subjects with ACL tear presented MRLs in 16% of cases. Compared with controls without meniscal lesions, knees with MRLs demonstrated accelerated degeneration of cartilage composition in the medial knee compartment over 2 years.
- 8 September 2020
- Published by Springer Nature in Skeletal Radiology
- Vol. 50 (3) , 551-558
Meniscal ramp lesions: frequency, natural history, and the effect on knee cartilage over 2 years in subjects with anterior cruciate ligament tears
Purpose (i) To investigate the frequency and natural evolution of meniscal ramp lesions (MRLs) on MRI in subjects with acute ACL tear and (ii) to compare knee cartilage compositional degeneration between subjects with MRLs and subjects without meniscal pathology over 2 years. Materials and methods Fifty-seven subjects with ACL tears (32 females; age 32.6 ± 8.3 years; BMI 24.5 ± 3.5 kg/m2) from a prospective study were screened for the presence of MRLs. Morphological (high-resolution 3D fast spin-echo) and compositional (T1ρ and T2 mapping) MRI was performed prior to and 2 years after ACL reconstruction. Follow-up MR images were assessed for changes in the signal intensity of the MRLs and the presence of meniscal tears. Differences of compositional parameters were compared between subjects with MRLs and without meniscal lesions using independent samples t tests. Results MRLs were found in 16% (9/56) of the subjects with ACL tears at baseline. Only one subject with MRLs developed a posterior horn meniscal tear over 2 years. In 12 knees, no meniscal tears were found, which were defined as controls. Most interestingly, cartilage ∆T1ρ of the medial femur and medial tibia increased significantly more in subjects with MRLs compared with controls (mean difference, MF = 6.0 ± 0.8 vs. 2.3 ± 0.6, p = 0.004, and MT = 4.4 ± 1.4 vs. 0.4 ± 0.6, p = 0.027) and medial femur ∆T2 over 2 years increased significantly more in MRL than in control knees (5.1 ± 2.5 ms vs. 2.2 ± 1.9 ms, p = 0.012). Conclusion Subjects with ACL tear presented MRLs in 16% of cases. Compared with controls without meniscal lesions, knees with MRLs demonstrated accelerated degeneration of cartilage composition in the medial knee compartment over 2 years.
- 6 October 2017
- Published by Springer Nature in European Radiology
- Vol. 28 (3) , 953-962
Association of weight change with progression of meniscal intrasubstance degeneration over 48 months: Data from the Osteoarthritis Initiative
To investigate the association of weight change over 48 months with progression of meniscal intrasubstance degeneration (MID).
- 6 October 2017
- Published by Springer Nature in European Radiology
- Vol. 28 (3) , 953-962
Association of weight change with progression of meniscal intrasubstance degeneration over 48 months: Data from the Osteoarthritis Initiative
To investigate the association of weight change over 48 months with progression of meniscal intrasubstance degeneration (MID).
- 16 December 2016
- Published by Springer Nature in European Radiology
- Vol. 27 (8) , 3499-3508
Cyclops lesions detected by MRI are frequent findings after ACL surgical reconstruction but do not impact clinical outcome over 2 years
Objectives To assess the impact of cyclops lesions with MRI in patients treated for anterior cruciate ligament (ACL) tears on clinical outcome. Methods In 113 patients (age 29.8 ± 10.5y; 55 females; BMI 24.8 ± 3.7 kg/m2) with complete ACL tear, 3 T-MRI scans were obtained before, 6-months, 1-year (n = 75) and 2-years (n = 33) after ACL reconstruction. Presence and volume of cyclops lesions were assessed. Clinical outcomes were measured using the Knee injury and Osteoarthritis Outcome Score (KOOS) and differences between time points (∆KOOS) were calculated. Changes of KOOS subscales were compared between patients with and without cyclops lesion. KOOS was also correlated with lesion volume. Results Cyclops lesions were found in 25% (28/113), 27% (20/75) and 33% (11/33) of patients after 6-months, 1- and 2-years, respectively. The lesion volume did not change significantly (P > 0.05) between time points, measuring 0.65 ± 0.59, 0.81 ± 0.70 and 0.72.9 ± 0.96 cm3, respectively. Clinical outcomes based on KOOS subscales were not significantly different in patients with cyclops lesions compared to those without cyclops lesions (each comparison P > 0.05), and no significant associations of clinical outcomes with lesion volume were found (P > 0.05). Conclusions Neither presence nor size of cyclops lesions within the first 2-years after ACL surgery were associated with inferior clinical outcome. Key Points • Cyclops lesions had a prevalence of 25% in patients after ACL reconstruction. • Subjects with cyclops lesions did not have an inferior clinical outcome. • Cyclops lesions developed within the first 6 months after surgery. • The size of cyclops lesions did not significantly change over a period of 2 years.
- 16 December 2016
- Published by Springer Nature in European Radiology
- Vol. 27 (8) , 3499-3508
Cyclops lesions detected by MRI are frequent findings after ACL surgical reconstruction but do not impact clinical outcome over 2 years
Objectives To assess the impact of cyclops lesions with MRI in patients treated for anterior cruciate ligament (ACL) tears on clinical outcome. Methods In 113 patients (age 29.8 ± 10.5y; 55 females; BMI 24.8 ± 3.7 kg/m2) with complete ACL tear, 3 T-MRI scans were obtained before, 6-months, 1-year (n = 75) and 2-years (n = 33) after ACL reconstruction. Presence and volume of cyclops lesions were assessed. Clinical outcomes were measured using the Knee injury and Osteoarthritis Outcome Score (KOOS) and differences between time points (∆KOOS) were calculated. Changes of KOOS subscales were compared between patients with and without cyclops lesion. KOOS was also correlated with lesion volume. Results Cyclops lesions were found in 25% (28/113), 27% (20/75) and 33% (11/33) of patients after 6-months, 1- and 2-years, respectively. The lesion volume did not change significantly (P > 0.05) between time points, measuring 0.65 ± 0.59, 0.81 ± 0.70 and 0.72.9 ± 0.96 cm3, respectively. Clinical outcomes based on KOOS subscales were not significantly different in patients with cyclops lesions compared to those without cyclops lesions (each comparison P > 0.05), and no significant associations of clinical outcomes with lesion volume were found (P > 0.05). Conclusions Neither presence nor size of cyclops lesions within the first 2-years after ACL surgery were associated with inferior clinical outcome. Key Points • Cyclops lesions had a prevalence of 25% in patients after ACL reconstruction. • Subjects with cyclops lesions did not have an inferior clinical outcome. • Cyclops lesions developed within the first 6 months after surgery. • The size of cyclops lesions did not significantly change over a period of 2 years.
- 18 August 2016
- Published by Springer Nature in Current Radiology Reports
- Vol. 4 (10) , 1-15
The Role of PET/CT in the Assessment of Primary Bone Tumors
- 18 August 2016
- Published by Springer Nature in Current Radiology Reports
- Vol. 4 (10) , 1-15
The Role of PET/CT in the Assessment of Primary Bone Tumors
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 11572
Correlation between local 18F-fluorodeoxyglucose PET/CT and T cell exhaustion for predicting treatment response in patients with advanced melanoma treated with checkpoint inhibitor mono-therapy.
11572 Background: Development of biomarkers to evaluate prolonged systemic treatment response is crucial for optimizing individual checkpoint inhibitor therapies. Glucose consumption rates assessed by 18F-FDG PET/CT have been used to stage and monitor the response to therapy in patients with melanoma. We aim to explore whether local 18F-FDG uptake can predict systemic response and how it correlates with intratumoral infiltration measured by the proportion of “exhausted” antigen experienced T cells (TEx)/Total CD8+ cells. Methods: Following core biopsies or surgical excision, freshly isolated tumor samples were digested and tumor infiltrating lymphocytes (TILs) were extracted and stained with T cell myeloid and activation markers, and analyzed with 14 color FACS. Patients were treated with either Nivolumab 3 mg/kg q2 week or Pembrolizumab 2 mg/kg q3 week. TEx was calculated as % CD8+, PD-1+, CTLA-4+ cells divided by total CD8+ T cells in the tumor sample. Thirty-nine patients (23 males) with measurable advanced melanoma were included. The closest in time, (49 ± 22 days), standard of care whole-body 18F-FDG PET/CT to the biopsy was used for analysis. Uptake was measured by maximum standardized uptake value (SUVmax) at the biopsied lesion. Treatment response was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST), for a period of 14±9 months. Results: Of the 18 patients with high TEx (more than 24%), 11 were in CR or PR at follow-up with a SUVmax of 15.8 an, compared to an SUVmax of 10.7 for the 7 patients in PD or SD. Nine of the 21 patients with low TEX (less than 24%) were in PR or CR with an SUVmax of 4.9, significantly lower than the SUVmax of the 12 patients in PD or SD, 10.4. Conclusions: When associated with TEx, local glucose utilization measured by 18F-FDG may be of help for predicting systemic response to check inhibitor mono-therapy. Variations in local increased glucose consumption may reflect several pathophysiologic pathways including different concentrations of activated lymphocyte populations, non-homogenous melanocytic tumoral densities and local inflammatory cellular migrations.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 11572
Correlation between local 18F-fluorodeoxyglucose PET/CT and T cell exhaustion for predicting treatment response in patients with advanced melanoma treated with checkpoint inhibitor mono-therapy.
11572 Background: Development of biomarkers to evaluate prolonged systemic treatment response is crucial for optimizing individual checkpoint inhibitor therapies. Glucose consumption rates assessed by 18F-FDG PET/CT have been used to stage and monitor the response to therapy in patients with melanoma. We aim to explore whether local 18F-FDG uptake can predict systemic response and how it correlates with intratumoral infiltration measured by the proportion of “exhausted” antigen experienced T cells (TEx)/Total CD8+ cells. Methods: Following core biopsies or surgical excision, freshly isolated tumor samples were digested and tumor infiltrating lymphocytes (TILs) were extracted and stained with T cell myeloid and activation markers, and analyzed with 14 color FACS. Patients were treated with either Nivolumab 3 mg/kg q2 week or Pembrolizumab 2 mg/kg q3 week. TEx was calculated as % CD8+, PD-1+, CTLA-4+ cells divided by total CD8+ T cells in the tumor sample. Thirty-nine patients (23 males) with measurable advanced melanoma were included. The closest in time, (49 ± 22 days), standard of care whole-body 18F-FDG PET/CT to the biopsy was used for analysis. Uptake was measured by maximum standardized uptake value (SUVmax) at the biopsied lesion. Treatment response was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST), for a period of 14±9 months. Results: Of the 18 patients with high TEx (more than 24%), 11 were in CR or PR at follow-up with a SUVmax of 15.8 an, compared to an SUVmax of 10.7 for the 7 patients in PD or SD. Nine of the 21 patients with low TEX (less than 24%) were in PR or CR with an SUVmax of 4.9, significantly lower than the SUVmax of the 12 patients in PD or SD, 10.4. Conclusions: When associated with TEx, local glucose utilization measured by 18F-FDG may be of help for predicting systemic response to check inhibitor mono-therapy. Variations in local increased glucose consumption may reflect several pathophysiologic pathways including different concentrations of activated lymphocyte populations, non-homogenous melanocytic tumoral densities and local inflammatory cellular migrations.
- 3 March 2016
- Vol. 60 (2) , 124-38
Pitfalls in [¹⁸F]FDG PET imaging in gynecological malignancies.
Gynecologic malignancies are the leading causes of cancer in women and they represent about 10 to 20% of all solid tumors. During the past few decades, technological advancements in the detection and staging have gained a pivotal role in all oncological processes, including the gynecological ones. Beyond ultrasound, computed tomography (CT) and magnetic resonance (MR) imaging that are conventionally used for anatomical imaging, [18F]FDG imaging and its hybrid further development as PET/CT has become a crucial tool due of its ability to combine functional metabolic and anatomic information, and the ability to image the entire whole body in a single examination. Since the introduction of integrated hybrid PET/CT systems into clinical practice the accurate analysis of the images has detected a number of limitations and pitfalls. The purpose of this review was to describe in detail the different pitfalls related to the use of [18F]FDG PET/CT in the gynecological malignancies, providing imaging examples and discussing possible ways to avoid misinterpretations.
- 3 March 2016
- Vol. 60 (2) , 124-38
Pitfalls in [¹⁸F]FDG PET imaging in gynecological malignancies.
Gynecologic malignancies are the leading causes of cancer in women and they represent about 10 to 20% of all solid tumors. During the past few decades, technological advancements in the detection and staging have gained a pivotal role in all oncological processes, including the gynecological ones. Beyond ultrasound, computed tomography (CT) and magnetic resonance (MR) imaging that are conventionally used for anatomical imaging, [18F]FDG imaging and its hybrid further development as PET/CT has become a crucial tool due of its ability to combine functional metabolic and anatomic information, and the ability to image the entire whole body in a single examination. Since the introduction of integrated hybrid PET/CT systems into clinical practice the accurate analysis of the images has detected a number of limitations and pitfalls. The purpose of this review was to describe in detail the different pitfalls related to the use of [18F]FDG PET/CT in the gynecological malignancies, providing imaging examples and discussing possible ways to avoid misinterpretations.